Latest news articles

Added 11 days ago Drug news

NEJM reports positive phase III trial of Cablivi to treat thrombocytopenic purpura.- Sanofi

The New England Journal of Medicine (NEJM) published positive results of the Phase III trial of Cablivi (nejm ) in adults...

Added 1 month ago Drug news

Amgen files sBLA for Nplate in adult ITP.- Amgen.

Amgen announced the submission of a Supplemental Biologics License Application (sBLA) to the FDA for Nplate (romiplostim) to include the...

Added 1 month ago Drug news

CHMP recommends approval of Lusutrombopag Shionogi for thrombocytopenia.- Shionogi.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...

Search all news articles for Coagulation and haemorrhagic disorders
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Guidelines

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

Venous thromboembolism (VTE) and bleeding are serious complications of cancer and its treatment. A recent survey of UK paediatric haematologists and oncologists identified a broad variety of practice in the management of issues...

Added 10 months ago

Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline.

Evidence-based guidelines were developed summarizing best practice for the assessment and management of acute joint bleeds and chronic synovitis in persons with haemophilia.

Added 7 months ago

A practical guideline for the haematological management of major haemorrhage

The aim of these updated guidelines is to provide recommendations for the haematological management of major haemorrhage in any clinical situation...

Added 3 years ago

Search all guidelines for Coagulation and haemorrhagic disorders
 

Journal articles

Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors.

Although factor Xa inhibitors have become a popular choice for chronic oral anticoagulation, effective drug reversal remains difficult due to a lack of specific antidote.

Added 5 months ago

Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety.

This review summarizes the experience reported using eltrombopag in ITP, paying attention to efficacy and safety.

Added 5 months ago

Heat-stable carbetocin versus oxytocin to prevent hemorrhage after vaginal birth

Postpartum hemorrhage is the most common cause of maternal death. Oxytocin is the standard therapy for the prevention of postpartum hemorrhage , but it requires cold storage, which is not available in many countries.

Added 6 months ago

Search all journal articles for Coagulation and haemorrhagic disorders
 

Clinical trials

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (HAVEN 5)

This randomized, multicenter, open-label, Phase 3 study is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII (FVIII) inhibitor status.

Added 10 months ago

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)

This multicenter, open-label, non-randomized study will assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg/kg) every 4 weeks...

Added 10 months ago

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older.

Added 10 months ago

Search all clinical trials for Coagulation and haemorrhagic disorders
 

CME

Dermatological emergencies in children

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0

Survival guide: safe prescribing for surgical inpatients

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90

Starting patients on oral anticoagulants in primary care: how to do it

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Coagulation and haemorrhagic disorders